CN115298220A - 抗体-药物偶联物及其医药用途 - Google Patents

抗体-药物偶联物及其医药用途 Download PDF

Info

Publication number
CN115298220A
CN115298220A CN202180021931.8A CN202180021931A CN115298220A CN 115298220 A CN115298220 A CN 115298220A CN 202180021931 A CN202180021931 A CN 202180021931A CN 115298220 A CN115298220 A CN 115298220A
Authority
CN
China
Prior art keywords
seq
antibody
group
trop
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180021931.8A
Other languages
English (en)
Chinese (zh)
Inventor
花海清
包如迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN115298220A publication Critical patent/CN115298220A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202180021931.8A 2020-03-24 2021-03-23 抗体-药物偶联物及其医药用途 Pending CN115298220A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010215320 2020-03-24
CN2020102153204 2020-03-24
PCT/CN2021/082294 WO2021190480A1 (fr) 2020-03-24 2021-03-23 Conjugué anticorps-médicament et son utilisation médicale

Publications (1)

Publication Number Publication Date
CN115298220A true CN115298220A (zh) 2022-11-04

Family

ID=77890947

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021931.8A Pending CN115298220A (zh) 2020-03-24 2021-03-23 抗体-药物偶联物及其医药用途

Country Status (3)

Country Link
CN (1) CN115298220A (fr)
TW (1) TW202144012A (fr)
WO (1) WO2021190480A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116212044A (zh) * 2021-12-03 2023-06-06 成都百利多特生物药业有限责任公司 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
WO2023241621A1 (fr) * 2022-06-16 2023-12-21 山东博安生物技术股份有限公司 Anticorps anti-liv-1 et conjugué anticorps-médicament
WO2024061173A1 (fr) * 2022-09-19 2024-03-28 上海美雅珂生物技术有限责任公司 Traitement du carcinome nasopharyngé à l'aide d'un conjugué d'anticorps ciblant egfr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014057687A1 (fr) * 2012-10-11 2014-04-17 第一三共株式会社 Conjugué anticorps-médicament
CA2933666C (fr) * 2013-12-25 2021-08-03 Sapporo Medical University Conjugue anticorps anti-trop2-medicament
CA2981543A1 (fr) * 2015-04-22 2016-10-27 Immunomedics, Inc. Isolement, detection, diagnostic et/ou caracterisation de cellules cancereuses trop-2 positives
TW201909926A (zh) * 2017-08-04 2019-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途
AU2019351427A1 (en) * 2018-09-30 2021-04-15 Changzhou Hansoh Pharmaceutical Co., Ltd. Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
WO2020228604A1 (fr) * 2019-05-10 2020-11-19 江苏豪森药业集团有限公司 Anticorps anti-trop-2, fragment de liaison à l'antigène de celui-ci et utilisation médicale associée
JP7467610B2 (ja) * 2019-09-18 2024-04-15 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． カンプトテシン誘導体及びその複合体

Also Published As

Publication number Publication date
WO2021190480A1 (fr) 2021-09-30
TW202144012A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
CN112351797B (zh) 抗b7-h4抗体-药物偶联物及其医药用途
WO2021190480A1 (fr) Conjugué anticorps-médicament et son utilisation médicale
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
JP2023505708A (ja) 抗クローディン抗体薬物複合体及びその医薬用途
CN112585168B (zh) 抗bcma抗体、其抗原结合片段及其医药用途
CN115279781A (zh) 抗体药物偶联物及其医药用途
JP2023506805A (ja) 抗ｃｅａ抗体－エキサテカン類似体複合体及びその医薬用途
TWI839556B (zh) 抗ｂｃｍａ抗體、其抗原結合片段及其醫藥用途
WO2023046003A1 (fr) Conjugué anticorps-médicament, son procédé de préparation et son utilisation pharmaceutique
TWI836070B (zh) 抗trop-2抗體、其抗原結合片段及其醫藥用途
CN115998900A (zh) 抗trop-2抗体药物偶联物及其医药用途
CN118139891A (zh) 抗体药物偶联物及其制备方法和医药用途
KR20230142530A (ko) 항체-약물 접합체 및 이의 의학적 용도
WO2022078424A1 (fr) Anticorps anti-trop-2, fragment de liaison à l'antigène de celui-ci ou mutant de celui-ci, et utilisation médicale associée

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082076

Country of ref document: HK